Autolus Therapeutics plc (AUTL) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-04-29

Key Insights

Autolus is implementing a 13% workforce reduction with approximately $8 million in restructuring costs, primarily to be recorded in H1 2026, indicating management's focus on operational efficiency amid ongoing business challenges.
The company reaffirmed its 2026 AUCATZYL net product revenue guidance of $120-135 million despite the restructuring, suggesting confidence in the commercial performance of its key therapeutic asset.
The workforce reduction began in H2 2025 and is expected to be completed by Q3 2026, indicating a phased approach to cost reduction that aims to minimize operational disruption while improving financial sustainability.
The 8-K includes extensive forward-looking statement disclaimers and risk acknowledgments, noting that actual implementation results may differ materially from current plans, reflecting uncertainty around execution and potential for additional unforeseen costs.

Want the newest filings?

This analysis covers the filing from 2026-04-29. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-04-16

Autolus Therapeutics plc has dismissed its independent registered public accounting firm, Ernst & Young LLP (UK), and appointed Ernst & Young LLP (US) as the new auditor effective for the fiscal year ending December 31, 2026.
The company's previous audit reports did not contain any adverse opinions or disclaimers, but there were material weaknesses in the company's internal control over financial reporting as of March 31, 2024.
The company did not consult the new auditor, Ernst & Young LLP (US), on any significant accounting or auditing matters during the prior two fiscal years.

Filed: 2026-04-08

Autolus Therapeutics plc hosted a virtual investor event focused on its Acute Lymphoblastic Leukemia (ALL) business, providing insights into its product pipeline and clinical development progress.
The presentation materials attached to the 8-K filing indicate that Autolus is making advancements in its ALL treatments, which could be of interest to investors.
The filing does not provide any financial updates or guidance, so the significance is primarily around the company's operational and pipeline developments.

Filed: 2026-03-27

Autolus Therapeutics reported its full year 2025 financial results, providing investors with an update on the company's operations and progress.
The company's corporate presentation indicates it is continuing to advance its pipeline of cell therapy candidates, which could be of interest to investors tracking its R&D developments.
The 8-K filing and accompanying materials do not appear to indicate any major unexpected events or changes, suggesting a relatively routine quarterly update for the company.

Filed: 2026-01-26

Autolus Therapeutics plc has entered into a 10-year Master Service Agreement with AGC Biologics S.p.A. for the manufacture and supply of lentiviral vector, a critical raw material for the company's CAR-T product pipeline.
The agreement includes commitments for Autolus to purchase a minimum of 14 batches of lentiviral vector in the first two years and a minimum of EUR 25 million in products and services over the subsequent five-year period.
The agreement also provides AGC with the first right to negotiate with Autolus regarding the provision of new manufacturing activities related to Autolus' obe-cel product.

Filed: 2026-01-12

Autolus Therapeutics announced preliminary unaudited net product revenue from sales of AUCATZYL (obe-cel) of $24 million for Q4 2025 and $75 million for the full year 2025, indicating strong commercial performance.
The company expects its current and projected cash, cash equivalents and marketable securities will be sufficient to fund operations into Q4 2027, providing a favorable cash runway outlook.
Autolus provided guidance for full year 2026 AUCATZYL net product revenue of $120 million to $135 million, suggesting continued growth expectations for the product.
The company highlighted the therapeutic potential and expected clinical benefits of AUCATZYL (obe-cel) for adult patients with r/r B-ALL and in additional indications like lupus nephritis and progressive multiple sclerosis, indicating pipeline expansion opportunities.

Other reports for Autolus Therapeutics plc

Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.